We identify the highly selective GSK3α,β inhibitor as an in vivo therapeutic capable of significantly normalizing the pathophysiological changes and cognitive disabilities caused by β-cat germline haploinsufficiency in a preclinical mouse model that displays key features of human CTNNB1 syndrome. This evidence concerns the gene CTNNB1 and Down syndrome.